Skip to main content
Top
Published in: Breast Cancer Research 1/2001

01-12-2002 | Paper Report

What centrosomes can teach us about tumor progression

Author: Karen Schmeichel

Published in: Breast Cancer Research | Issue 1/2001

Login to get access

Excerpt

During mitosis, centrosomes organize microtubules into spindle structures that mediate proper chromosomal segregation. Increased centrosome number, a characteristic common to a majority of breast tumors, is thought to cause chromosomal mis-segregations and thus lead to tumor aneuploidy. Because interphase centrosomes nucleate and organize the microtubule cytoskeleton, centrosome abnormalities could also contribute to cellular malignancy by disrupting overall cellular architecture. Given the dual significance of the centrosome, the authors examined the relationship between centrosomes (i.e. number, size and activity) and chromosomal instability (CIN), p53 mutation, tissue differentiation and aneuploidy in a total of 27 tissue samples from either normal breast (n = 7) or from tumors of five histologic grades ( diploid [n = 3], monosomy 17 [n = 3], stable aneuploid [n = 5], unstable aneuploid [n = 9]). …
Literature
1.
go back to reference Lingle W, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA . 2002, 99: 1978-1983.CrossRefPubMedPubMedCentral Lingle W, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA . 2002, 99: 1978-1983.CrossRefPubMedPubMedCentral
Metadata
Title
What centrosomes can teach us about tumor progression
Author
Karen Schmeichel
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2002-76551

Other articles of this Issue 1/2001

Breast Cancer Research 1/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine